A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations
This study is testing a new medication called zotiraciclib to see if it can help treat recurring brain tumors known as diffuse gliomas. Researchers are focusing on patients whose tumors have specific genetic markers called IDH1 or IDH2 mutations, as they hope this drug will help stop these cancer cells from growing.
This trial is for people aged 15 and older who have a diffuse glioma that has returned after previous treatments. You must have a confirmed IDH1 or IDH2 gene mutation and meet specific health criteria regarding your recent medical history.
Participants will take the study drug as a capsule at home on a set schedule and visit the clinic about once a month for check-ups and heart tests. You will also have regular brain MRIs every eight weeks to help doctors see how the treatment is working.
The study is currently recruiting volunteers and is taking place in Bethesda, Maryland. Participants may be involved in the study for up to 18 months, depending on their health and how they respond to the drug.
- 1The goal is to test a new, targeted drug for a specific type of recurring brain tumor.
- 2Participants take their medication at home, reducing the need for constant clinic visits.
- 3The research team provides close monitoring through regular blood tests and brain scans to ensure patient safety.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.